NCT06069622View on ClinicalTrials.gov

Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment

RecruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

October 1, 2025

Study Completion Date

October 30, 2025

Conditions
Overweight and Obesity
Interventions
DIAGNOSTIC_TEST

24-hour ambulatory blood pressure

24-hour ambulatory blood pressure, blood, and urine will be obtained prior to semaglutide therapy and after 20 weeks of semaglutide therapy.

DIETARY_SUPPLEMENT

Liberal salt diet

Participants will be on a liberal salt (about 200 mEq sodium/day) diet for 7 days.

Trial Locations (1)

02115

RECRUITING

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

Charles A. King Trust Postdoctoral Fellowship Program

UNKNOWN

lead

Brigham and Women's Hospital

OTHER